Galecto, Inc.

NasdaqCM:GLTO Stock Report

Market Cap: US$1.3b

Galecto Management

Management criteria checks 2/4

Galecto's CEO is Hans Schambye, appointed in Jan 2020, has a tenure of 6.08 years. total yearly compensation is $1.43M, comprised of 36.8% salary and 63.2% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $3.85M. The average tenure of the management team and the board of directors is 1.4 years and 5.8 years respectively.

Key information

Hans Schambye

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage36.80%
CEO tenure6.1yrs
CEO ownership0.3%
Management average tenure1.4yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Jan 10
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

May 17
Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Feb 01
Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10
Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23
We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29
Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

CEO Compensation Analysis

How has Hans Schambye's remuneration changed compared to Galecto's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$16m

Jun 30 2025n/an/a

-US$17m

Mar 31 2025n/an/a

-US$18m

Dec 31 2024US$1mUS$526k

-US$21m

Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$965kUS$506k

-US$38m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$1mUS$473k

-US$62m

Sep 30 2022n/an/a

-US$61m

Jun 30 2022n/an/a

-US$60m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$3mUS$512k

-US$52m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$4mUS$387k

-US$35m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$48m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$479kUS$360k

-US$42m

Compensation vs Market: Hans's total compensation ($USD1.43M) is below average for companies of similar size in the US market ($USD5.15M).

Compensation vs Earnings: Hans's compensation has increased whilst the company is unprofitable.

CEO

Hans Schambye (59 yo)

6.1yrs
Tenure
US$1,429,550
Compensation

Dr. Hans T. Schambye, MD, Ph D, is CEO of Boost Pharma Aps from February 10, 2026 and is Director since August 2025. Dr. Schambye serves as Member of Board of Directors at BioInnovation Institute.Dr. Scha...

Leadership Team

NamePositionTenureCompensationOwnership
Hans Schambye
Co-Founder6.1yrsUS$1.43m0.29%
$ 3.8m
Lori Firmani
Chief Financial Officer1.5yrsUS$561.89k0.058%
$ 765.5k
Garrett Winslow
Senior VP4.8yrsUS$897.37k0.12%
$ 1.5m
Ulf Nilsson
Co-Founderno datano datano data
Hakon Leffler
Co-Founderno datano datano data
Tariq Sethi
Co-Founderno datano datano data
Sherwin Sattarzadeh
Chief Operating Officerless than a yearno datano data
Matthew Kronmiller
EVP of Strategy & Chief Business Officer1.3yrsno datano data
Becker Hewes
Chief Medical Officerless than a yearno datano data
1.4yrs
Average Tenure
51yo
Average Age

Experienced Management: GLTO's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Hans Schambye
Co-Founder6.1yrsUS$1.43m0.29%
$ 3.8m
Carl Goldfischer
Independent Chairman of the Board6.1yrsUS$114.20k0.024%
$ 315.7k
Alexander Maximiliaan Eggermont
Member of the Clinical Advisory Board – Oncologyno datano datano data
Amit Munshi
Independent Director5.8yrsUS$57.99k0%
$ 0
Jayson Donald Dallas
Independent Director5.3yrsUS$63.97k0%
$ 0
Christopher Cain
Independent Directorless than a yearno datano data
Jonathan Fallowfield
Member of Clinical Advisory Board – Liver cirrhosisno datano datano data
Adam Mead
Member of the Clinical Advisory Board - Myelofibrosisno datano datano data
Aaron Gerds
Member of the Clinical Advisory Board - Myelofibrosisno datano datano data
Claire Harrison
Member of the Clinical Advisory Board - Myelofibrosisno datano datano data
John Mascarenhas
Member of the Clinical Advisory Board - Myelofibrosisno datano datano data
Raajit Rampal
Member of the Clinical Advisory Board - Myelofibrosisno datano datano data
5.8yrs
Average Tenure
57yo
Average Age

Experienced Board: GLTO's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/12 06:24
End of Day Share Price 2026/02/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galecto, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Andrew BerensLeerink Partners LLC